NCT04354857 (Anosmie-COVID) is a clinical trial of olfactory and gustatory tests in COVID-19, sponsored by Centre Hospitalier Universitaire de Nīmes.

Who is sponsoring NCT04354857?

NCT04354857 is sponsored by Centre Hospitalier Universitaire de Nīmes.

What drugs are being tested in NCT04354857?

Interventions in NCT04354857: olfactory and gustatory tests.

Is NCT04354857 still recruiting?

NCT04354857 is currently completed. Last updated 21 June 2021.

Last reviewed 2021-06-21 · How we verify

NCT04354857: Anosmie-COVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection

Completed Last updated 21 June 2021

What this trial tests

trial testing olfactory and gustatory tests in COVID-19 in 454 participants. Completed in 30 November 2020.

Timeline

27 March 2020

Primary endpoint
31 July 2020

30 November 2020

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nīmes
Status	Completed
Study type	OBSERVATIONAL
Enrollment	454
Start date	27 March 2020
Primary completion	31 July 2020
Estimated completion	30 November 2020
Sites	1 location across France

Drugs / interventions tested

olfactory and gustatory tests

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

SARS-Cov-2 Damage on the Nervous System and Mental Health.
Boulkrane MS, Ilina V, Melchakov R, Arisov M, et al · · 2022 · cited 4× · PMID 34191699 · DOI 10.2174/1570159x19666210629151303

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

NCT07403474 — Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Ther · Phase 4 · not yet recruiting
NCT07455981 — Work Organization and Gambling Addiction · not yet recruiting
NCT07403500 — Evaluation of the Short-term Effectiveness of Spinal Manipulation to Treat Acute and Subacute Low Back Pain. · NA · not yet recruiting
NCT07342010 — Bicarbonate Addition to Lidocaine-Epinephrine in Surgery Under WALANT · Phase 4 · not yet recruiting
NCT07305727 — A Radiomic MRI Predictive Model for Response to Concomitant Chemoradiotherapy in Locally Advanced Cervical Cancer · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04354857 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nīmes
Last refreshed: 21 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04354857.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing